{"id":1639,"date":"2026-01-27T19:20:06","date_gmt":"2026-01-27T19:20:06","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T14:52:46","modified_gmt":"2026-06-26T14:52:46","slug":"ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/","title":{"rendered":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases"},"content":{"rendered":"\n<p><strong>Montreal (QC), (January 28, 2026) \u2014<\/strong>&nbsp;Ocythera, Inc., a Montreal-based biopharmaceutical company developing innovative therapies for rare bone diseases, today announced it has secured seed financing from adMare BioInnovations and Fonds Impulsion, managed by Investissement Quebec and funded by the gouvernement du Qu\u00e9bec. This investment will accelerate Ocythera\u2019s development of highly selective CYP26B1 inhibitors, a novel approach to treating rare bone disorders with improved safety and efficacy.<\/p>\n\n\n\n<p>\u201cThis funding marks a critical milestone for Ocythera as we advance toward developing new therapeutic options for patients who currently have very few,\u201d said Dr. Martin Petkovich, Scientific Founder of Ocythera and Professor at Queen\u2019s University. \u201cWe are grateful for the Fonds Impulsion\u2019s confidence in our vision and for adMare BioInnovation\u2019s pivotal role in transforming this academic research into a company ready to attract investment and scale, and for their continued support. The scientific evidence is compelling and we are excited to advance this novel therapy and bring its life-changing potential closer to patients.\u201d<\/p>\n\n\n\n<p>\u201cBy supporting start-ups such as Ocythera, our government is placing innovation at the heart of public health. We are proud to help accelerate the growth of these small and medium sized enterprises, which are bringing innovative solutions to market while contributing to economic growth and the continued expansion of Qu\u00e9bec\u2019s life sciences ecosystem,\u201d said Samuel Poulin, Minister Delegate for the Economy and Small and Medium Sized Enterprises and Minister responsible for Youth.<\/p>\n\n\n\n<p>\u201cThrough investments like the one made in Ocythera, the Fonds Impulsion provides emerging companies with access to the critical financing they need to support their development and accelerate the advancement of their innovations. These efforts help strengthen Qu\u00e9bec\u2019s technology and life sciences ecosystem,\u201d added Alex Laverdi\u00e8re, Vice President, Venture Capital at Investissement Qu\u00e9bec.<\/p>\n\n\n\n<p>Ocythera is an adMare BioInnovations portfolio company, created through a four-year collaboration with Queen\u2019s University. As Canada\u2019s engine for life sciences company creation and growth, adMare provided pre-seed capital along with scientific and industry expertise to generate robust preclinical data and intellectual property, create value, and build a strong and efficient operating structure, laying the foundation for Ocythera\u2019s growth.<\/p>\n\n\n\n<p>-30-<\/p>\n\n\n\n<p><strong>About Ocythera<\/strong><\/p>\n\n\n\n<p>Based in Montreal, Ocythera is developing a new generation of non-retinoid therapies for rare bone diseases. Originating from pivotal research made at Queen\u2019s University and drug discovery from adMare BioInnovations, the company is advancing highly selective compounds with an improved safety and efficacy profile, targeting one of the enzymes involved in the metabolism of retinoic acids. To learn more about Ocythera, visit&nbsp;<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.ocythera.com%2F&amp;data=05%7C02%7Cbmoir%40admarebio.com%7Cae412cee8b894548721008de39996a36%7Cd185790b96324fa9a3f77dbdfc84ae08%7C0%7C0%7C639011528242917358%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=OQZpGvblilcbTBlSWYslYcGWuNTEj1Q1g9dOzz8qqQY%3D&amp;reserved=0\">ocythera.com.<\/a><\/p>\n\n\n\n<p><strong>About Fonds Impulsion&nbsp;<\/strong><\/p>\n\n\n\n<p>The Impulsion Fund is a venture capital fund dedicated to early stage, high growth potential innovative companies at the pre-seed and seed stages. We invest from the very first financing rounds, with initial investments ranging from $250,000 to $2 million, and have the capacity to reinvest in subsequent funding rounds.<\/p>\n\n\n\n<p>Our mission is clear: to accelerate the growth of local start-ups by providing cornerstone capital, tailored support, and privileged access to a strategic network of partners committed to their development.<\/p>\n\n\n\n<p><strong>About Queen&#8217;s University<\/strong><br>Founded in 1841, Queen&#8217;s University, Canada, is an internationally ranked research-intensive university with more than 31,000 students and 5,000 faculty and staff. Queen&#8217;s is known for research in areas such as cancer detection and treatment, geoengineering, materials science, AI and supercomputing, and is home to the 2015 Nobel Prize in Physics. Queen&#8217;s welcomes researchers and students from around the world and is one of Canada&#8217;s leading universities. To learn more, please visit&nbsp;<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4578828-1%26h%3D4268293779%26u%3Dhttps%253A%252F%252Fwww.queensu.ca%252F%26a%3Dqueensu.ca%2B%25C2%25A0&amp;data=05%7C02%7Cbmoir%40admarebio.com%7Cab8e5b5d091f424f215008de4fbbbdaa%7Cd185790b96324fa9a3f77dbdfc84ae08%7C0%7C0%7C639035864940919044%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=j9rX2Cq2WZchzUuJn5vWQxwOQzuzhev4TedQNUtqV0c%3D&amp;reserved=0\">queensu.ca &nbsp;<\/a>&nbsp;<\/p>\n\n\n\n<p><strong>About adMare BioInnovations<\/strong><\/p>\n\n\n\n<p>adMare&nbsp;BioInnovations&nbsp;is Canada\u2019s&nbsp;life sciences company creation&nbsp;engine, focused on building and scaling strong, investable companies.&nbsp;Our&nbsp;unique&nbsp;model identifies&nbsp;breakthrough&nbsp;innovations&nbsp;addressing unmet patient needs&nbsp;and&nbsp;supports early company creation and growth through&nbsp;pre-seed investment,&nbsp;commercial&nbsp;R&amp;D&nbsp;and&nbsp;IP and business development expertise. This approach helps establish&nbsp;the&nbsp;scientific&nbsp;validation, value,&nbsp;and operating&nbsp;foundations&nbsp;needed&nbsp;to&nbsp;build&nbsp;globally competitive&nbsp;Canadian life science companies.&nbsp;To date, adMare has&nbsp;helped&nbsp;create&nbsp;39&nbsp;companies&nbsp;that have attracted $2.5 billion&nbsp;in&nbsp;risk capital,&nbsp;achieved&nbsp;a combined value of $5.8 billion, and created approximately&nbsp;1,000 jobs.&nbsp;&nbsp;<\/p>\n\n\n\n<p>adMare also&nbsp;provides more than&nbsp;200,000 square feet of turnkey lab facilities&nbsp;and delivers industry-ready talent and executive leadership&nbsp;development&nbsp;programs&nbsp;to help&nbsp;Canadian&nbsp;life science companies scale and succeed. Learn more at&nbsp;<a href=\"https:\/\/www.admarebio.com\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.admarebio.com<\/a>&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/cdn.ca.yapla.com\/company\/CPYHw7b49QP8orSGdiTUqZmVt\/asset\/files\/Ocythera%20Announcement_IQFunding_Jan2026_ENG.pdf\">Read the press release in PDF<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montreal (QC), (January 28, 2026) \u2014&nbsp;Ocythera, Inc., a Montreal-based biopharmaceutical company developing innovative therapies for rare bone diseases, today announced it has secured seed financing from adMare BioInnovations and Fonds [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1640,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[82],"class_list":["post-1639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare\" \/>\n<meta property=\"og:description\" content=\"Montreal (QC), (January 28, 2026) \u2014&nbsp;Ocythera, Inc., a Montreal-based biopharmaceutical company developing innovative therapies for rare bone diseases, today announced it has secured seed financing from adMare BioInnovations and Fonds [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T19:20:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T14:52:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1198\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases\",\"datePublished\":\"2026-01-27T19:20:06+00:00\",\"dateModified\":\"2026-06-26T14:52:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/\"},\"wordCount\":794,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ocythera_eng-1769531742.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/\",\"name\":\"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ocythera_eng-1769531742.png\",\"datePublished\":\"2026-01-27T19:20:06+00:00\",\"dateModified\":\"2026-06-26T14:52:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ocythera_eng-1769531742.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ocythera_eng-1769531742.png\",\"width\":1198,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare","og_description":"Montreal (QC), (January 28, 2026) \u2014&nbsp;Ocythera, Inc., a Montreal-based biopharmaceutical company developing innovative therapies for rare bone diseases, today announced it has secured seed financing from adMare BioInnovations and Fonds [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/","og_site_name":"adMare","article_published_time":"2026-01-27T19:20:06+00:00","article_modified_time":"2026-06-26T14:52:46+00:00","og_image":[{"width":1198,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases","datePublished":"2026-01-27T19:20:06+00:00","dateModified":"2026-06-26T14:52:46+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/"},"wordCount":794,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/","name":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png","datePublished":"2026-01-27T19:20:06+00:00","dateModified":"2026-06-26T14:52:46+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/ocythera_eng-1769531742.png","width":1198,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/ocythera-secures-seed-financing-from-admare-bioinnovations-and-fonds-impulsion-to-advance-therapies-for-rare-bone-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1639"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1639\/revisions"}],"predecessor-version":[{"id":1641,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1639\/revisions\/1641"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1640"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1639"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}